Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)
Status:
Completed
Trial end date:
2021-04-21
Target enrollment:
Participant gender:
Summary
This research evaluates the effectiveness of a new drug called belatacept (Nulojix) for the
prevention of acute rejection and preservation of kidney function in transplant patients.
Belatacept was approved in 2011 by the United States Food and Drug Administration (FDA) and
is being marketed as Nulojix. The pharmaceutical company sponsoring this study is
Bristol-Myers Squibb.
Belatacept is a prescription medicine used in adults to prevent transplant rejection in
people who have received a kidney transplant. Transplant rejection happens when the body's
immune system senses that the new transplanted kidney is different or foreign, and attacks
it. Belatacept is used with corticosteroids and certain other medicines to help prevent
rejection of your new kidney.
The purpose of the research is to understand whether the new drug, belatacept, is better than
other anti-rejection drugs, such as cyclosporine and tacrolimus that are typically used in
the treatment against kidney rejection in transplant patients.